Patrick Nef, PhD co-founder and CEO. Prof. Patrick Nef holds a PhD and has over 25 years of experience in academia, biotechnology industry, small and large pharmaceuticals and non-for-profit public-private partnership foundation. He served as Chief Business Officer at Medicines for Malaria Venture from 2008 to 2011 to assist their efforts to reduce the burden of malaria in endemic countries by discovering, developing and facilitating delivery of new, effective and affordable antimalarial drugs, Chief Scientific Officer at Synosia Therapeutics Inc. from 2006 to 2008 to develop drugs for neuro-degenerative and psychiatric disorders, Chief Executive Officer at Faust Pharmaceutical SA in 2005 to develop CNS drugs and as Global Business Director, Vice-President & Disease Area Head for CNS at F. Hoffmann-La Roche Ltd. from 1996-2005. Before that he was Assistant Professor in the Biochemistry Department at the University of Geneva, Switzerland from 1992.
Sebastien Tabruyn, PhD Chief Scientific Officer (CSO). Sebastien Tabruyn holds a PhD in Molecular Biology from the University of Liege (Belgium). After 15 years of experience as Project leader in renowned international academic research institutes including UCSF (California, USA), the Centre for Cancer Biology (Adelaide, Australia) and the University of Maastricht (Netherlands), he joined TransCure bioServices in 2013 as Head of Molecular Biology and Oncology. Sebastien Tabruyn published 35 peer-reviewed publications in the field of Oncology, Angiogenesis, Inflammation and Immunity.
Kiave-Yune HoWangYin, PhD Director of Innovation. Kiave HoWangYin holds a PhD in Immunology / Oncology from the Paris 7 University (France). She worked for 5 years in the Center of Cardiovascular Research (Paris) as scientist in the field of inflammation and angiogenesis. She published more than 10 papers in peer-reviewed international journals in oncology and inflammation.
Catherine Verhaeghe, PhD Director of Operations. Catherine Verhaeghe holds a PhD in Molecular Biology from the University of Liege (Belgium). She joined David Erle Lab at UCSF (USA) where she identified new molecules involved in goblet cell hyperplasia in lung and intestinal diseases. She has expertise in Project/Team Management, In vivo mouse models, Inflammation, Signalling Pathway and Oncology. She published more than 10 papers in peer-reviewed international journals in the field of Cystic fibrosis, airway and intestinal inflammation, oncology.
Antoine Poskin, DVM, PhD Veterinary Chief Officer and Animal Facility Manager. Antoine started his career as a veterinarian, then worked as scientific researcher for Iprabio (Mons, Belgium), the Blood Brain Barrier Laboratory (LBHE, Lens, France) and Sciensano (formerly Veterinary and Agrochemical Research Centre, Brussels, Belgium). Antoine published 11 peer-reviewed articles and obtained a PhD in Veterinary Science from the University of Liege (Belgium). After his PhD, he first joined the respiratory franchise of Novartis as Medical Sciences Liaison, then moved to TransCure bioServices as Veterinary Chief Officer and Animal Facility Manager. At TransCure bioServices, he is in charge of the animal facility and makes sure that corporate policy meets the highest quality and ethical standards for our clients dedicating his time to the up and coming AAALAC accreditation.
TransCure bioServices SAS is accredited by the french Ministère de l’Enseignement Supérieur et de la Recherche MESR and the Haut Conseil des Biotechnologies to perform in vivo pharmacology studies for worldwide international customers.
As a preferred provider CRO for our customer’s in vivo pharmacology studies, our team members emphasise competence, transparency, and enthusiasm. We are very pro-active, SOP driven to deliver the best, high quality results you are looking for. Our recognised alliance management skills is appreciated by our clients.
Regarding animal welfare, we apply the strictest regulation in compliance with the national laws of France, guidelines and regulations to underpin our own global bioethical chart:
1 – We are committed to the 3Rs which are, Replacement, Reduction and Refinement, to good science and to the responsible use of animals, which are treated with the highest standards of care and ethics. We only work with highly qualified staffs which are trained regularly in order to ensure the best treatment for research animals. We have started in 2018 the AAALAC accreditation/validation process, and have successfully been audited by large pharma companies since the company creation.
2 – In addition to the inspections by government authorities, we have a formal program of regular peer reviews of our internal animal and laboratory research facilities, conducted by the biopark’s ethical committee and an independent veterinarian.